Antipsychotic-induced weight gain: A comprehensive research synthesis

American Journal of Psychiatry

Volumn 156, Issue 11, 1999, Pages 1686-1696

  Allison, David B ^a   Mentore, Janet L ^b   Heo, Moonseong ^b   Chandler, Linda P ^b   Cappelleri, Joseph C ^b   Infante, Ming C ^b   Weiden, Peter J ^b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE PLUS PERPHENAZINE; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; LOXAPINE SUCCINATE; MESORIDAZINE; MESORIDAZINE BESYLATE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PROCHLORPERAZINE; PROCHLORPERAZINE MALEATE; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; ZIPRASIDONE;

ARTICLE; DRUG RESEARCH; HUMAN; MEDICAL LITERATURE; OBESITY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; CLOZAPINE; CONFIDENCE INTERVALS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MOLINDONE; PIPERAZINES; PLACEBOS; PSYCHOTIC DISORDERS; RESEARCH DESIGN; THIAZOLES; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0032751075     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (96)

1. Bernstein JG: Induction of obesity by psychotropic drugs. Ann NY Acad Sci 1987; 499:203-215
2. Schotte A, Janssen PF, Megens AA, Leysen JE: Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res 1993; 63:191-202
3. Brief DJ: Chronic treatment with neuroleptic drugs and weight gain, Dissertation Abstracts International 1985; 45(11B):3653
4. Salomon MS: Histamine: a new factor in the control of feeding behavior. Dissertation Abstracts International 1992; 53(2B): 1102
5. Allison DB, Pi-Sunyer FX: Obesity treatment: examining the premises. Endocrine Practice 1995; 1:353-364
6. Centers for Disease Control: Update: prevalence of overweight among children, adolescents, and adults - United States, 1988-1994. MMWR Morb Mortal Wkly Rep 1997; 46: 198-202
7. National Institute of Health: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. Obes Res 1998; 6(suppl 2):51S-209S
8. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, Weiden PJ, Cheskin LJ: The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999; 60:215-220
9. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL: Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996; 37:68-73
10. McKee HA, D'Arcy PF, Wilson PJ: Diabetes and schizophrenia - a preliminary study. J Clin Hosp Pharm 1986; 11:297-299
11. Tsuang MT, Perkins K, Simpson JC: Physical diseases in schizophrenia and affective disorder. J Clin Psychiatry 1983; 44:42-46
12. Brambilla F, Guastalla A, Guerrini A, Riggi F, Rovere C, Zanoboni A, Zanoboni-Muciaccia W: Glucose-insulin metabolism in chronic schizophrenia. Dis Nerv Syst 1976; 37:98-103
13. Hyman SE, Arana GW, Rosenbaum JF: Handbook of Psychiatric Drug Therapy, 3rd ed. New York, Little, Brown, 1995
14. Allison DB, Faith MS, Gorman BS: Publication bias in obesity treatment trials. Int J Obes 1996; 20:931-937
15. Begg CB, Berlin JA: Publication bias and the dissemination of clinical research. J Natl Cancer Inst 1989; 81:107-115
16. White HD: Scientific communication and literature retrieval, in The Handbook of Research Synthesis. Edited by Cooper H, Hedges LV. New York, Russell Sage Foundation, 1994, pp 41-55
17. Cooper H, Hedges LV (eds): The Handbook of Research Synthesis. New York, Russell Sage Foundation, 1994
18. Aberg A: Viktforandring i samband med psykofarmakabehandling. Opusc Med 1964; 20:13-19
19. Heimberg C, Gallacher F, Gur RC, Gur RE: Diet and gender moderate clozapine-related weight gain. Human Psychopharmacology 1995; 10:367-371
20. Rosenthal R: Meta-Analytic Procedures for Social Research. Newbury Park, Calif, Sage Publications, 1991
21. Hogg RV, Craig AT: Introduction to Mathematical Statistics, 4th ed. New York, Macmillan, 1978
22. Tippett LHC: The Methods of Statistics. London, Williams & Norgate, 1931
23. Norusis MJ: SPSS for Windows: Base System User's Guide, Release 7.5. Chicago, SPSS, 1997
24. Shadish WR, Haddock CK: Combining estimates of effect size, in The Handbook of Research Synthesis. Edited by Cooper H, Hedges LV. New York, Russell Sage Foundation, 1994, pp 261-281
25. Gopalaswamy AK, Morgan R: Too many chronic menially disabled patients are too fat. Acta Psychiatr Scand 1985; 72: 254-258
26. Sen A, Srivastava M: Regression Analysis. New York, Springer-Verlag, 1990
27. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry 1997; 154(April suppl)
28. Treatment of schizophrenia: steering committee, the expert consensus. J Clin Psychiatry 1996; 57(suppl 12B):3-58
29. Hedges LV: Fixed effects models, in The Handbook of Research Synthesis. Edited by Cooper H, Hedges LV. New York, Russell Sage Foundation, 1994, pp 285-299
30. Raudenbush SW: Random effects models. Ibid, pp 301-321
31. Westfall PH, Young SS: Resampling-Based Multiple Testing: Examples and Methods for P-Value Adjustment. New York, John Wiley & Sons, 1993
32. Bechelli LPC, lecco MC, Acioli A, Pontes MC: A double-blind trial of haloperidol decanoate and pipothiazine palmitate in the maintenance treatment of schizophrenics in a public outpatient clinic. Curr Ther Res 1985; 37:662-671
33. Darling HF: Haloperidol in 60 criminal psychotics. Dis Nerv Syst 1971; 32:31-34
34. Falloon I, Watt DC, Shepherd M: A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychol Med 1978; 8:59-70
35. Frazier JA, Gordon CT, McKenna K, Lenane MC, Jih D, Rapoport JL: An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1994; 33:658-663
36. Hanlon TE, Ota KY, Kurland AA: Comparative effects of fluphenazine, fluphenazine-chlordiazepoxide and fluphenazine-imipramine. Dis Nerv Syst 1970; 31:171-177
37. Hemphill RE, Pascoe FD, Zabow T: Acute and chronic schizophrenia and gross behavior disorders. S Afr Med J 1975; 49: 2121-2125
38. Huttunen MO, Piepponen T, Rantanen H, Larmo I, Nyholm R, Raitasuo V: Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallelgroup trial. Acta Psychiatr Scand 1995; 91:271-277
39. Lindstrom LH: A retrospective study on the long-term efficacy of clozapine in 96 schizophrenic and schizoaffective patients during a 13-year period. Psychopharmacology (Berl) 1989; 99:S84-S86
40. Naber D, Holzbach R, Perro C, Hippius H: Clinical management of clozapine patients in relation to efficacy and side effects. Br J Psychiatry Suppl 1992; 17:54-59
41. Nair NPV, Zicherman V, Schwartz G: Dopamine and schizophrenia. Can Psychiatr Assoc J 1977; 22:285-293
42. Norris DL, Israelstam K: Clozapine (Leponex) overdosage (letter). S Afr Med J 1975; 49:385
43. Povlsen UJ, Noring U, Fog R, Gerlach J: Tolerability and therapeutic effect of clozapine. Acta Psychiatr Scand 1985; 71: 176-185
44. Rada RT, Donlon PT: Piperacetazine vs thioridazine for the control of schizophrenia in outpatients. Psychosomatics 1972; 13:373-376
45. Sletten IW, Gershon S. The effect of chlorpromazine on water and electrolyte balance. J Nerv Ment Dis 1966; 142:25-31
46. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG: Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997; 54:549-557
47. Winkelman NW: A clinical and socio-cultural study of 100 psychiatric patients started on chlorpromazine 20 and one-half years ago. Am J Psychiatry 1964; 20:861-869
48. Wistedt B, Persson T, Hellbom E: A clinical double-blind comparison between haloperidol decanoate and fluphenazine decanoate. Clin Ther Res 1984; 35:804-814
49. Young E: Hospital experience with fluphenazine enanthate. Dis Nerv Syst 1970; 31:705-709
50. Gallant DM, Bishop MP, Steele CA, Bishop G, Guerrero-Figueroa R: Molindone: a crossover evaluation of capsule and tablet formulations in severely ill schizophrenic patients. Curr Ther Res 1973; 15:915-918
51. Gardos G, Cole JO: Weight reduction in schizophrenics by molindone. Am J Psychiatry 1977; 134:302-304
52. Kellner R, Rada RT, Egelman A, Macaluso B: Long-term study of molindone hydrochloride in chronic schizophrenics. Curr Ther Res 1976; 20:686-694
53. Conley RR, Carpenter WT Jr, Tamminga CA: Time to clozapine response in a standardized trial. Am J Psychiatry 1997; 154:1243-1247
54. Muller-Siecheneder F, Muller MJ, Hillert A, Szegedi A, Wetzel H, Benkert O: Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol 1998; 18: 111-120
55. Nemeroff CB: Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 1997; 58(suppl 10):45-49
56. Jeste DV, Klausner M, Brecher M, Clyde C, Jones R: A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial (ARCS Study Group: Assessment of Risperidal in a clinical setting). Psychopharmacology (Berl) 1997; 131:239-247
57. Lindstrom E, Eriksson B, Hellgren A, von Knorring L, Eberhard G: Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995; 17: 402-412
58. Keks N, McGrath J, Lambert T, Catts S, Vaddadi K, Burrows G, Varghese F, George T, Hustig H, Burnett P, Kerr K, Zorbas A, Hill C, Stedman T, Johnson G, Leibert B, Copolov D, Mackenzie M, Dillenbeck C: The Australian multicentre doubleblind comparative study of remoxipride and thioridazine in schizophrenia. Acta Psychiatr Scand 1994; 90:358-365
59. Weinsier RL, Bracco D, Schutz Y: Predicted effects of small decreases in energy expenditure on weight gain in adult women. Int J Obes Relat Metab Disord 1993; 17:693-700
60. Beasley CM Jr, Tollefson GD, Tran PV: Safety of olanzapine. J Clin Psychiatry 1997; 58(suppl 10):13-17:19-21 (figure N)
61. Planansky K, Heilizer F: Weight changes in relation to the characteristics of patients on chlorpromazine. J Clin and Experimental Psychopathology and Q Rev Psychiatry Neurol 1959; 20:53-57
62. Amdisen A. Drug-produced obesity: experiences with chlorpromazine, perphenazine, and clopenthixol. Dan Med Bull 1964; 11:182-189
63. Lawson WB, Karson CN: Clinical correlates of body weight changes in schizophrenia. J Neuropsychiatry Clin Neurosci 1994; 6:87-188
64. Bustillo JR, Buchanan RW, Irish D, Breier A: Differential effect of clozapine on weight: a controlled study. Am J Psychiatry 1996; 153:817-819
65. Umbricht DS, Pollack S, Kane JM: Clozapine and weight gain. J Clin Psychiatry 1994; 55(Sept suppl B):157-160
66. Institute of Medicine: Weighing the Options: Criteria for Evaluating Weight-Management Programs. Washington, DC, National Academy Press, 1995
67. Fulton JE, Shekelle RB: Cigarette smoking, weight gain, and coronary mortality: results from the Chicago Western Electric Study. Circulation 1997; 96:1438-1444
68. Lee IM, Paffenbarger RS Jr: Changes in body weight and Iongevity. JAMA 1992; 268:2045-2049
69. Barnes-Josiah D, Potter JD, Sellers TA, Himes JH: Early body size and subsequent weight gain as predictors of breast cancer incidence (Iowa, United States). Cancer Causes Control 1995; 6:112-118
70. Cerhan JR, Torner JC, Lynch CF, Rubenstein LM, Lemke JH, Cohen MB, Lubaroff DM, Wallace RB: Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ rural health study (United States). Cancer Causes Control 1997; 8:229-238
71. Suadicani P, Hein HO, Gyntelberg F: Weight changes and risk of ischaemic heart disease for middle-aged and elderly men: an 8-year follow-up in the Copenhagen male study. J Cardiovasc Risk 1997; 4:25-32
72. Walker M, Wannamethee G, Whincup PH, Shaper AG: Weight change and risk of heart attack in middle-aged British men. Int J Epidemiol 1995; 24:694-703
73. Sakurai Y, Nakamura K, Sakurai M, Muto T, Tanaka H: Relationship between weight change in young adulthood and the risk of NIDDM: the Sotetsu study. Diabetes Care 1997; 20: 978-982
74. Hagg S, Joelsson L, Mjorndal T, Spigset O, Oa G, Dahlqvist R: Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998; 59:294-299
75. Popli AP, Konicki PE, Jurjus GJ, Fuller MA, Jaskiiw GE: Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997; 58:108-111
76. Mukherjee S, Roth SD, Sandyk R, Schnur DB: Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance. Psychiatry Res 1998; 29:17-27
77. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC: Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44:778-783
78. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154:457-465
79. Kolakowska T, Gadhvi H, Molyneux S: An open clinical trial of fenfluramine in chronic schizophrenia: a pilot study. Int J Clin Psychopharmacol 1987; 2:83-88
80. Sletten IW, Ognjanov V, Menendez S, Sundland D, El-Toumi A: Weight reduction with chlorphentermine and phentermine in obese psychiatric patients during chlorpromazine therapy. Curr Ther Res 1967; 9:570-575
81. Bernard JL: Rapid treatment of gross obesity by operant techniques. Psychol Rep 1968; 23:663-666
82. Harmatz MG, Lapuc P: Behavior modification of overeating in a psychiatric population. J Consult Clin Psychol 1968; 32: 583-587
83. Knox JM: A study of weight reducing diets in psychiatric in-patients. Br J Psychiatry 1980; 136:287-289
84. Rotatori AF, Fox R, Wicks A: Weight loss with psychiatric residents in a behavioral self-control program. Psychol Rep 1980; 6:483-486
85. Sletten I, Mou B, Cazenave M, Gershon S: Effects of caloric restriction on behavior and body weight during chlorpromazine therapy. Dis Nerv Syst 1967; 28:519-522
86. Stanton JM: Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995; 21:463-472
87. Baptista T, Lopez ME, Teneud L, Contreras Q, Alastre T, de Quijada M, Araujo de Baptista E, Alternus M, Weiss SR, Musseo E, Paez X, Hernandez L: Amantadine in the treatment of neuroleptic-induced obesity in rats: behavioral, endocrine and neurochemical correlates. Pharmacopsychiatry 1997; 30:43-54
88. Correa N, Opler LA, Kay SR, Birmaher B: Amantadine in the treatment of neuroendocrine side-effects of neuroleptics. J Clin Psychopharmacol 1987; 7:91-95
89. Guerciolini R: Mode of action of orlistat. Int J Obes Relat Metab Disord 1997; 21(suppl 3):S12-S23
90. National Task Force on the Prevention and Treatment of Obesity: Long-term pharmacotherapy in the management of obesity. JAMA 1996; 276:1907-1915
91. Dietz AJ: Amphetamine-like reactions to phenylpropanolamine. JAMA 1981; 245:601-602
92. Khan SA, Spiegel DA, Jobe PC: Psychotomimetic effects of anorectic drugs. Am Fam Physician 1987; 36:107-112
93. Oswald I: Fenfluramine and psychosis (letter). Br Med J 1974; 4:103
94. Raison CL, Klein HM: Psychotic mania associated with fenfluramine and phentermine use (letter). Am J Psychiatry 1997; 154:711
95. Shannon PJ, Leonard D, Kidson MA: Fenfluramine and psychosis (letter). Br Med J 1974; 3:576
96. Robinson S, Winnik HZ: Severe psychotic disturbances following crash diet weight loss. Arch Gen Psychiatry 1973; 29: 559-562